Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Success rates are higher for clinical trials that incorporate selective pharmacogenomics and pharmacogenetics (PGX) biomarkers, according to data from Informa's Trialtrove. Given the challenges of designing and administering trials to secure regulatory approval in areas of unmet medical need, the data provide some basis for optimism in realizing the promise of targeted, personalized therapies that improve health outcomes for individual patients.
Latest From Market Intelligence
Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
Seattle Genetics added to its antibody-drug conjugate pipeline in a $2 billion deal with Immunomedics; LabCorp could buy the CRO PPD for $8 billion. Representing the majority of the $3.9 billion in biopharma financing, Perrigo sold to RPI Finance Trust its royalty stream on Tysabri for $2.2 billion.
Free content: There were 132 personalized medicines on the market in 2016, compared with just five in in 2008, according to the Personalized Medicine Coalition. And 27% of new molecular entities approved by the FDA in 2016 can be can be classified as a personalized medicine. That's a big jump from 2005, when personalized medicines accounted for just 5% of NME approvals. A look at some other key numbers in this rapidly growing field.
Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.
Free article: What In Vivo has been saying about personalized medicine in this century.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.